IPO and Fundraising - The company completed its Initial Public Offering (IPO) on February 12, 2026, raising gross proceeds of $230 million from the sale of 23 million units at $10.00 per unit[20]. - An additional $6.65 million was raised through the sale of 665,000 Private Placement Units at $10.00 per unit, bringing total gross proceeds to $236.65 million[21]. - Following the IPO, a total of $230,000,000 was placed in a Trust Account, which may only be invested in U.S. government securities or held in cash until the completion of a Business Combination[177]. - The company has approximately $1,495,000 of proceeds held outside the Trust Account to cover costs associated with dissolution if necessary[119]. - The company has received a total of $300,000 under the IPO Promissory Note to cover expenses related to the Initial Public Offering, with $172,158 fully repaid upon IPO completion[202]. Business Combination Timeline and Requirements - The company must complete its initial Business Combination by February 12, 2028, or face termination and distribution of funds in the Trust Account[23]. - The company has until February 12, 2028, to consummate its initial business combination, with provisions for shareholder redemption if unable to do so[57]. - The company may not complete the initial Business Combination if the aggregate cash consideration required exceeds the available cash, which could lead to returning all Class A Ordinary Shares submitted for redemption[108]. - Public Shareholders may redeem their shares irrespective of their voting decision, and the redemption process will be conducted in compliance with SEC regulations[107]. - The company may seek shareholder approval to extend the Combination Period beyond February 12, 2028, which could reduce the amount held in the Trust Account and adversely affect the ability to consummate the initial Business Combination[154]. Financial Position and Revenue Generation - The company has not yet generated any operating revenues and does not expect to do so until the consummation of its initial Business Combination[19]. - The company reported a net loss of $46,064 for the period from inception (April 3, 2025) through December 31, 2025, primarily due to general and administrative costs[195]. - The company has not paid any cash dividends to date and does not intend to do so prior to completing its initial Business Combination[171]. - As of December 31, 2025, the company had a working capital deficit of $169,035 and cash held outside the Trust Account of approximately $1,665,000[200]. - The company may need additional financing to complete its initial Business Combination if the transaction requires more cash than available from the Trust Account or if significant Public Shares are redeemed[76]. Management and Strategy - The management team has a track record of completing several mergers and acquisitions, supported by their work with a reputable investment bank[38]. - The company aims to identify attractive opportunities in sectors such as AI, digital infrastructure, healthcare, and cryptocurrency across EMEA and LatAm regions[34][35]. - The management team believes that their extensive networks will provide a robust pipeline of target companies for potential investments[37]. - The company anticipates structuring its initial Business Combination to acquire 100% of the equity interests or assets of the target business, but may also acquire less than 100% if it meets certain objectives[60]. - The company expects to incur significant costs in pursuing its acquisition plans as an early-stage growth company[185]. Market Opportunities and Trends - The AI and digital infrastructure industries are projected to contribute $15.7 trillion to global GDP by 2030, with a CAGR of 36.6% from 2024 to 2030[43]. - The global sports market is expected to reach $680 billion by 2028, while the entertainment and media market is projected to exceed $3.4 trillion[43]. - U.S. healthcare expenditure is estimated to reach $5.0 trillion in 2024, with a projected EBITDA of $987 billion by 2028[43]. - The energy transition sector is projected to grow to $5.4 trillion by 2031, with a CAGR of 9.7% from 2024 to 2031[48]. - The global cryptocurrency market is expected to grow to $15.4 billion by 2032, with an annual growth rate of 13.1% from 2024 to 2032[48]. Risks and Challenges - The company may face significant dilution for public shareholders due to the conversion of Founder Shares and potential additional equity issuances[30]. - The company may face increased competition from other SPACs for attractive targets, which could lead to improved financial terms demanded by target companies[68]. - The company may lack business diversification post-initial Business Combination, relying on the performance of a single business, which could expose it to economic and regulatory risks[80][81]. - The ongoing geopolitical conflicts, including the Russia-Ukraine conflict and tensions in the Middle East, may materially adversely affect the company’s ability to find a target business for the initial Business Combination[155]. - The company may face significant risks related to cybersecurity incidents, which could adversely affect its financial condition and operations[163]. Shareholder Rights and Redemption - Public shareholders will have the opportunity to redeem their Class A Ordinary Shares at a price equal to the amount in the Trust Account, initially set at $10.00 per share[95]. - The company requires 7,291,000, or approximately 31.7%, of the 23,000,000 Public Shares sold in its Initial Public Offering to be voted in favor of the initial Business Combination for approval[102]. - A Public Shareholder holding more than 15% of the shares sold in the Initial Public Offering will be restricted from seeking redemption rights without prior consent[109]. - The decision to conduct redemptions may be made without a shareholder vote, depending on the circumstances surrounding the initial Business Combination[98]. - The company intends to require Public Shareholders to deliver share certificates or electronically transfer shares to exercise redemption rights[111]. Regulatory and Compliance Issues - The company is classified as an "emerging growth company," allowing it to take advantage of certain exemptions from reporting requirements[135]. - The company will remain an emerging growth company until it meets specific revenue or market value thresholds[137]. - The company is also classified as a "smaller reporting company," which allows for reduced disclosure obligations[138]. - Regulatory review and approval requirements may hinder the ability to complete an initial Business Combination[147]. - The company’s securities may be subject to delisting from Nasdaq, limiting Public Shareholders' ability to trade their securities[151].

Financial Results Announcement - Beeline Holdings, Inc. announced financial results for Q4 2025 on March 30, 2026[5] - The press release detailing the financial results is included as Exhibit 99.1[5] Compliance and Classification - The company is not classified as an emerging growth company under the Securities Act[4] - The filing is made in compliance with the Securities Exchange Act of 1934[10] Report Details - The report does not include any financial statements or exhibits beyond the press release[7]

Financial Performance - AEON Biopharma reported cash and cash equivalents of $3.0 million as of December 31, 2025, which does not include $4.2 million from PIPE financing received in January 2026[13]. - The company strengthened its balance sheet through $6 million PIPE financing and a note exchange, reducing outstanding debt by more than 90%[5][10]. - AEON reported a net loss of $39.2 million for the year ended December 31, 2025, compared to a net income of $42.0 million in 2024[26]. - Total operating expenses for 2025 were $12.8 million, a decrease from $73.0 million in 2024[26]. - AEON's total assets increased to $5.6 million in 2025, up from $3.1 million in 2024[24]. Product Development - The primary structure of ABP-450 exhibited a 100% sequence match to BOTOX®, based on sequence coverage of 93–99% across all five proteins[6]. - AEON plans to complete the majority of its analytical comparability program in 2026, following positive initial comparative analytical results[7][16]. - The company aims to request a BPD Type 2b meeting in 2026 to discuss the next phase of the development program for ABP-450[16]. Market Opportunity - AEON's U.S. therapeutic neurotoxin market opportunity exceeds $3.0 billion annually, representing a significant potential for biosimilar entry[17]. Leadership Changes - The company appointed John Bencich as Chief Financial Officer in March 2026, bringing over 25 years of experience in corporate strategy and capital markets[11].

Financial Performance - Revenue for the year ended December 31, 2025 was $25.8 million, a decrease of $1.1 million or 4.1% compared to $26.9 million in 2024[179]. - CVD Equipment segment revenue was $18.1 million, representing 70.0% of overall revenue, while SDC segment revenue was $7.6 million, accounting for 29.5% of overall revenue[181][182]. - Gross profit increased to $7.3 million with a gross profit margin of 28.3%, up from $6.1 million and 22.5% in 2024[185]. - Net loss for the year was $1.6 million, an improvement of $0.3 million or 16.5% compared to a net loss of $1.9 million in 2024[199]. - Cash balance at December 31, 2025, was $8.7 million, down from $12.6 million at December 31, 2024[168]. Bookings and Backlog - CVD Equipment Corporation's bookings for 2025 were approximately $13.0 million, a decrease of 53.7% compared to 2024's bookings of $28.1 million, attributed to macroeconomic issues[51]. - The backlog as of December 31, 2025, was approximately $6.6 million, a decrease of $12.8 million from $19.4 million as of December 31, 2024[79]. - Total bookings for 2025 were approximately $13.0 million, a decrease of $15.1 million or 53.7% compared to $28.1 million in 2024, attributed to macroeconomic issues[168]. - The order backlog at December 31, 2025 was approximately $6.6 million, down from $19.4 million at December 31, 2024[184]. Strategic Initiatives - The company entered into an agreement to sell its SDC division for approximately $16.9 million in cash, expected to close in Q2 2026[22]. - CVD plans to use approximately $15.0 million of the net cash proceeds from the SDC sale to enhance financial flexibility and support shareholder value initiatives[23]. - The transformation strategy aims to reduce annual operating costs by approximately $1.8 million through workforce reduction and outsourcing of certain components[26]. - The company transitioned its operating model for the CVD Equipment division from vertically integrated fabrication to outsourced fabrication to reduce fixed operating costs[80]. - The company completed a workforce reduction plan in Q4 2025, incurring approximately $0.1 million in severance and other charges[169]. Market and Demand Conditions - The company has observed continued weakness in demand for its PVT product line, negatively impacting sales due to global overcapacity of silicon carbide wafers[40]. - Demand for products may decline due to budgetary and political restrictions affecting research and industrial applications[98]. - Volatile demand for products makes it difficult to budget expenses accurately, leading to potential fluctuations in quarterly operating results[127]. - The lengthy sales cycle for products ranges from several months to over one year, complicating revenue forecasting[95]. Customer Concentration and Risks - Two customers represented 27.6% and 13.7% of revenues for the year ended December 31, 2025, highlighting significant customer concentration risk[71]. - In 2025, two customers represented 27.6% and 13.7% of total revenues, indicating a highly concentrated customer base[94]. Operational Challenges - Supply chain disruptions have resulted in increased costs and delays, impacting revenue recognition and gross profit margins[112]. - Recent global inflation has adversely affected costs, necessitating measures to mitigate its impact on gross margins[114]. - The company faces significant competition from larger firms with greater resources, which could impair pricing and market share[109]. - Tariffs and geopolitical developments may restrict access to materials and increase costs, negatively affecting business operations[112]. - The company is experiencing reduced availability of raw materials and components due to geopolitical developments, which may negatively impact operations and revenue[115]. - Manufacturing facilities in Central Islip and Saugerties, New York, are at risk from weather events, particularly hurricanes, which could disrupt production and affect customer commitments[116]. - The company faces cybersecurity risks that could lead to substantial costs and operational disruptions if successful attacks occur[117]. Research and Development - The company’s research and development activities focus on Si deposition, SiC growth, and the growth of carbon nanotubes, graphene, and nanowires[68]. - Significant investments in research and development are necessary to keep pace with technological changes, but there is no assurance that future revenues will recover these costs[120]. - Research and development expenses were $2.8 million, or 10.8% of revenue, compared to $2.6 million, or 9.8% in 2024[186]. Compliance and Regulatory Issues - The company is subject to environmental regulations, and non-compliance could result in significant liabilities and operational disruptions[125]. - Compliance with conflict minerals regulations may increase costs and complicate supply chains, potentially harming customer relationships[126].

Financial Position - As of December 31, 2025, Annexon reported cash, cash equivalents, and short-term investments of approximately $238.3 million, providing a runway into the second half of 2027[1] - Total current assets decreased from $316,461 in 2024 to $242,191 in 2025, a decline of approximately 23.4%[14] - Cash and cash equivalents increased significantly from $49,498 in 2024 to $162,051 in 2025, representing a growth of 226.5%[14] - Total liabilities rose from $56,966 in 2024 to $65,923 in 2025, an increase of about 15.5%[14] - Stockholders' equity decreased from $293,105 in 2024 to $211,648 in 2025, a decline of approximately 27.8%[14] - The accumulated deficit increased from $710,699 in 2024 to $917,389 in 2025, reflecting a worsening of about 29.1%[14] - Accounts payable increased from $10,426 in 2024 to $14,931 in 2025, a rise of approximately 43.3%[14] - Additional paid-in capital grew from $1,003,685 in 2024 to $1,128,917 in 2025, an increase of about 12.5%[14] - Total assets decreased from $350,071 in 2024 to $277,571 in 2025, a decline of approximately 20.7%[14] - Operating lease liabilities, current, increased from $2,518 in 2024 to $2,908 in 2025, a rise of about 15.4%[14] - Other non-current assets increased from $3,235 in 2024 to $8,546 in 2025, a growth of approximately 164.5%[14] Research and Development - Research and development (R&D) expenses for Q4 2025 were $42.7 million, compared to $43.4 million in Q4 2024, while total R&D expenses for the year were $184.7 million, up from $119.4 million in 2024[8] - The company anticipates topline data from the Phase 3 ARCHER II trial of vonaprument in geographic atrophy (GA) to be reported in Q4 2026[3] - The Phase 3 ARCHER II trial involves 659 patients and is designed to evaluate visual preservation as the primary endpoint, with enrollment completed in July 2025[3] - ANX1502 is advancing as the first oral C1 inhibitor for autoimmune diseases, with proof-of-concept data expected in 2026[1] - The ongoing FORWARD study aims to broaden experience with tanruprubart across Western geographies, including pediatric patients, to support a broad intended label for GBS treatment[8] Expenses - General and administrative (G&A) expenses for Q4 2025 were $7.6 million, down from $9.1 million in Q4 2024, with total G&A expenses for the year at $31.7 million compared to $34.6 million in 2024[8] - The net loss attributable to common stockholders for Q4 2025 was $48.3 million, or $0.28 per share, compared to a net loss of $48.6 million, or $0.33 per share, in Q4 2024[8] Regulatory and Market Developments - A Marketing Authorization Application (MAA) for tanruprubart has been filed in Europe, with a planned Biologics License Application (BLA) submission in 2026 supported by ongoing FORWARD study data[1] - The company has established a global registration path for vonaprument with U.S. and European regulators, receiving PRIME designation from the EMA[3]

Regulatory Approvals and Compliance - INmune Bio plans to file a Marketing Authorization Application (MAA) in the UK by July 2026 and in the EU by September 2026, followed by a Biologics License Application (BLA) with the FDA targeted for December 2026[23]. - The FDA granted Rare Pediatric Disease Designation (RPDD) to CORDStrom on December 13, 2024, and Orphan Drug Designation (ODD) on January 6, 2025, providing various development incentives[37][39]. - The company intends to hold a pre-BLA meeting with the FDA to discuss the planned BLA submission for CORDStrom this year[40]. - Regulatory compliance is critical, with extensive requirements for product development and marketing authorization from agencies like the FDA[85]. - The company must navigate various regulatory processes, including submitting an Investigational New Drug Application (IND) before commencing clinical trials[88]. - The FDA reviews a Biologics License Application (BLA) within 60 days to determine if it is substantially complete before filing[98]. - Standard review of a BLA is targeted to be completed within ten months, while priority review aims for six months[98]. - The FDA may require additional clinical trials post-approval, known as Phase 4 studies, to gather more information about the product[93]. - The FDA offers expedited programs like fast track and breakthrough therapy designations to facilitate the development of products addressing serious conditions[102][106]. - A BLA must include all relevant data from preclinical and clinical studies, including negative results, and requires a substantial application user fee[95]. - The FDA may issue a Complete Response letter detailing deficiencies in a BLA, which must be addressed before approval[100]. - Manufacturing facilities must comply with Current Good Manufacturing Practices (cGMP) to ensure product safety and quality[99]. - The Pediatric Research Equity Act requires data on safety and effectiveness for pediatric populations in BLA submissions[97]. - The FDA may condition approval on Risk Evaluation and Mitigation Strategies (REMS) to manage known risks associated with a product[101]. - The FDA grants orphan drug designation to products intended to treat rare diseases affecting fewer than 200,000 individuals in the U.S.[109]. - A product with orphan drug designation that receives FDA approval is entitled to seven years of orphan drug exclusivity, preventing approval of similar products for the same indication[110]. - Orphan drug exclusivity may be lost if the FDA finds the designation request materially defective or if the manufacturer cannot assure sufficient quantities of the product[111]. - The FDA's interpretation of orphan drug exclusivity has evolved, potentially covering the full scope of the orphan-designated disease regardless of narrower approvals[112]. - Post-approval, products are subject to ongoing FDA regulation, including record-keeping, adverse experience reporting, and compliance with cGMPs[113]. - The FDA may withdraw approval if regulatory compliance is not maintained or if new safety issues arise post-market[114]. - The Biologics Price Competition and Innovation Act (BPCIA) allows for an abbreviated approval pathway for biosimilars, with a 12-year exclusivity period for reference products[120]. - A reference biologic is granted twelve years of exclusivity from the date of first licensure, with additional exclusivity for interchangeable biosimilars[121]. - Patent owners may apply for up to a five-year extension after BLA approval to compensate for time lost during the FDA regulatory process[124]. - Pharmaceutical companies must comply with various healthcare regulations, including the Anti-Kickback Statute and the False Claims Act, to avoid legal scrutiny[126][128]. - The U.S. federal Physician Payments Sunshine Act requires manufacturers to report payments to healthcare professionals, with compliance starting January 1, 2023[131]. - The Inflation Reduction Act (IRA) allows CMS to negotiate drug prices and cap out-of-pocket costs, with the first ten drugs selected for negotiation announced on August 29, 2023[145]. - The ACA significantly changed healthcare financing in the U.S., affecting pharmaceutical pricing and reimbursement, with ongoing challenges expected[150]. - The Bipartisan Budget Act of 2018 increased point-of-sale discounts under Medicare Part D from 50% to 70% for eligible beneficiaries during the coverage gap[151]. - Compliance with HIPAA and state privacy laws is critical, with significant penalties for violations, including civil and criminal fines[135]. - Coverage and reimbursement for new products depend on third-party payors, with significant uncertainty regarding approval and reimbursement levels[142]. - The IRA's inflation rebate provision requires drug manufacturers to pay rebates if drug prices increase faster than inflation, effective in 2023[145]. - The ACA's provisions include new methodologies for calculating Medicaid rebates, impacting pharmaceutical companies' financials[150]. - Third-party payors are increasingly scrutinizing drug prices and may challenge the cost-effectiveness of new products, impacting sales[143]. - Compliance costs and legal risks are heightened due to varying state laws on data privacy and security, complicating operations[138]. - The company is facing increased governmental scrutiny regarding drug pricing practices, with potential impacts on financial condition and operations[152]. - The Inflation Reduction Act (IRA) has not diminished ongoing legislative interest in specialty drug pricing, indicating a continued push for transparency and cost reduction in prescription drugs[153]. - The company must comply with various international regulations for drug marketing authorization, which can vary significantly by country and may affect product launch timelines[156]. - The European Union's General Data Protection Regulation (GDPR) imposes strict obligations on the processing of personal data, with potential fines of up to €20 million or 4% of total worldwide annual turnover for noncompliance[162]. - The centralized authorization procedure in the EU requires a marketing authorization (MA) that is valid across all member states, with an evaluation timeframe of 210 days, excluding clock stops[168]. - The company must submit a Risk Management Plan (RMP) for new marketing authorization applications, which is continually updated throughout the product's lifecycle[171]. - Marketing authorizations have an initial duration of five years, with the possibility of renewal based on a reevaluation of the risk-benefit balance[172]. - The UK has implemented a new International Recognition Procedure (IRP) for marketing authorizations, effective January 1, 2024, allowing for fast-tracked reviews based on approvals from other jurisdictions[166]. - The company is subject to various regulations in jurisdictions outside the United States, which govern aspects such as clinical trials, manufacturing, and marketing practices[154]. - The approval process for drugs in different countries can significantly affect the commercial feasibility of product launches, particularly if satisfactory pricing is not achieved[156]. - In the EU, innovative medicinal products, referred to as New Chemical Entities (NCEs), qualify for eight years of data exclusivity and ten years of marketing exclusivity[178]. - An additional non-cumulative one-year period of marketing exclusivity is possible if the MA holder obtains authorization for new therapeutic indications during the data exclusivity period[179]. - The data exclusivity period begins on the date of the product's first MA in the EU, allowing generic applications after eight years, but they cannot launch until two years later, totaling ten years[180]. - The EMA's Committee for Orphan Medicinal Products (COMP) reassesses orphan drug designation in parallel with MA review, providing up to ten years of market exclusivity for orphan indications[184]. - The 10-year market exclusivity for orphan drugs may be reduced to six years if the product no longer meets orphan designation criteria by the end of the fifth year[186]. - The current drafts of the European pharmaceutical legislation reform propose shortening data exclusivity periods from eight to six years and extending market exclusivity for orphan medicines under certain conditions[187]. - The UK has introduced a system for incentivizing the development of orphan medicines, retaining market exclusivity benefits similar to the EU[188]. - Companies developing new medicinal products in the EU must submit a Pediatric Investigation Plan (PIP) and conduct pediatric clinical trials, which can lead to extensions of market exclusivity[189]. - The EMA launched the Priority Medicines (PRIME) scheme to facilitate the development of products for unmet medical needs, providing benefits like early regulatory dialogue and potentially accelerated assessment[191]. - Non-compliance with pharmacovigilance obligations can lead to the variation, suspension, or withdrawal of the MA for the product, impacting profitability[196]. Clinical Trials and Product Development - The pivotal trial for CORDStrom showed a significant reduction in itch severity of over 27% at 6 months in patients with severe RDEB[29]. - Approximately 2,000 individuals in the US, UK, and EU suffer from RDEB, representing a substantial unmet medical need for systemic treatment options[27]. - The company has entered a licensing agreement with Great Ormond Street Hospital, gaining exclusive access to clinical study data for commercial use in exchange for an initiation milestone payment of approximately $0.3 million and a potential development milestone of up to £6 million (approximately $8.1 million) upon receiving marketing authorization[35]. - XPro1595 has completed Phase I and II trials for Alzheimer's Disease, with the Phase II trial involving 208 patients and top-line data received in June 2025[45]. - In the Phase II trial of XPro, the primary and key secondary endpoints were not met, but a trend favoring XPro was observed in a subgroup of patients with both amyloid positivity and higher inflammation[48]. - XPro demonstrated a 91% reduction in neuronal injury markers and a 43% reduction in p-Tau217 levels after 3 months of therapy[42]. - CORDStrom is manufactured in the UK and is designed to be a scalable, cost-effective treatment for complex inflammatory diseases[25]. - The enriched population showed a beneficial effect of XPro on neuropsychiatric symptoms (NPI) with an effect size of -0.23 and a p-value of 0.2[51]. - A Phase I/II trial of INKmune for metastatic castrate-resistant prostate cancer was initiated, with top-line data expected approximately 6 months after full enrollment[65]. - The company confirmed regulatory alignment with the FDA on the proposed integrated Phase 2b/3 clinical development strategy for XPro in early Alzheimer's disease[62]. - The enriched population (50% of the total sample, n=100) showed trends toward improvement with XPro on primary and key secondary endpoints[51]. - INKmune is a replication-incompetent derivative of the proprietary INB-16 cell line, with applications aimed at enhancing NK cell efficacy against cancer[70]. - The company has 13 issued patents and 27 pending patent applications across various therapeutic programs[67]. - CORDStrom technology aims to improve batch-to-batch consistency and scalable manufacturing for mesenchymal stem/stromal cell products[68]. - The DN-TNF platform technology includes 14 pending applications and 8 issued patents for treating diseases[69]. - The company holds 4 pending patents and 5 issued patents globally for INKmune, with patent terms extending to 2043[70]. - The Immune Ventures License Agreement grants the company an exclusive worldwide license for INKmune, with milestone and royalty payments required[76]. - The latest patent under the Immune Ventures Agreement is set to expire on March 15, 2038, after which the company will have a royalty-free license[77]. - The company has a license agreement with the University of Pittsburgh, which includes annual maintenance fees and milestone payments, expiring by June 26, 2037[80]. - The Xencor License Agreement allows the company to develop and sell products incorporating XPro, with royalties based on sales and sublicensing[82]. - The company executed a license for clinical trial data related to CORDStrom, with an upfront payment of £250,000 (approximately $0.3 million) and a potential milestone payment of up to £6,000,000 (approximately $8.1 million)[84]. Financial Performance and Funding - As of December 31, 2025, the company reported an accumulated deficit of $209,037,000, reflecting significant investments in research and development and general administrative expenses[213]. - The company incurred net losses of $45.9 million and $42.1 million for the years ended December 31, 2025 and 2024, respectively[216]. - Cash and cash equivalents as of December 31, 2025, were $24.8 million, indicating limited liquidity for ongoing operations[216]. - The public float of the company's common stock was approximately $36.8 million as of December 31, 2025, which may limit capital-raising efforts[220]. - The company has a history of losses since its inception in September 2015 and may never achieve or sustain profitability[216]. - The company is substantially dependent on the success of its product candidates, particularly CORDStrom, which may never receive regulatory approval[212]. - The costs of clinical development are expected to increase significantly at each phase, making it uncertain when the company will generate revenue[217]. - The company intends to pursue additional funding to support its strategic plan, but there is no assurance of success[215]. - Regulatory compliance is critical, as failure to meet requirements could result in fines, suspension of clinical trials, or withdrawal of approvals[207]. - The company faces intense competition in its targeted markets, with many competitors having greater resources[210].

Regulatory Submissions and Approvals - Sangamo Therapeutics initiated a rolling submission of a Biologics License Agreement (BLA) to the FDA for ST-920, a gene therapy for Fabry disease, under the Accelerated Approval pathway[3]. - Sangamo's ST-503 received Fast Track Designation from the FDA for the treatment of intractable pain due to small fiber neuropathy[10]. - The company anticipates completing the rolling BLA submission for isaralgagene civaparvovec, with expectations for FDA approval[21]. - The company is advancing the Chemistry, Manufacturing and Controls (CMC) module for ST-920, with BLA submission completion expected by summer 2026, subject to funding[10]. Financial Performance - Total revenues for 2025 were $39.6 million, a decrease of $18.2 million compared to $57.8 million in 2024, primarily due to a reduction in revenue from the collaboration agreement with Genentech[8][9]. - The consolidated net loss for the fourth quarter of 2025 was $37.4 million, compared to a net loss of $23.4 million in the same period of 2024[5]. - Revenues for Q4 2025 were $14,228,000, a 88.5% increase from $7,551,000 in Q4 2024[26]. - The net loss for Q4 2025 was $37,419,000, compared to a net loss of $23,396,000 in Q4 2024, resulting in a basic and diluted net loss per share of $0.11[26]. - Sangamo's operating loss for the year ended December 31, 2025, was $121,239,000, an increase from $103,969,000 in 2024[26]. Operating Expenses - Total operating expenses on a GAAP basis for 2025 were $160.8 million, slightly down from $161.8 million in 2024[13]. - Total operating expenses for Q4 2025 were $52,431,000, up from $33,541,000 in Q4 2024, primarily driven by increased research and development costs[26]. - Research and development expenses for the year ended December 31, 2025, were $112,670,000, slightly up from $111,521,000 in 2024[26]. - The company expects total operating expenses in 2026 to be in the range of approximately $120 million to $140 million on a GAAP basis[17]. Cash and Assets - Cash and cash equivalents as of December 31, 2025, were $20.9 million, down from $41.9 million as of December 31, 2024[15]. - Cash and cash equivalents decreased to $20,948,000 as of December 31, 2025, down from $41,918,000 a year earlier[27]. - Total assets declined to $59,745,000 as of December 31, 2025, compared to $101,635,000 in 2024[27]. Future Plans and Funding - Sangamo raised over $130 million in funding since the start of 2025 through non-dilutive license fees, milestone payments, and equity financing[1]. - Sangamo plans to secure a commercialization partner for its Fabry disease program to enhance its therapeutic potential[21]. - Sangamo's financial guidance for 2026 is contingent upon securing adequate additional funding to support its operations[22].

Financial Performance - The net loss for the year ended December 31, 2025, was $11.2 million, compared to a net loss of $24.5 million for 2024[415]. - As of December 31, 2025, the company had $14.7 million in cash and an accumulated deficit of $130.2 million[415]. - Total revenue for the year ended December 31, 2025, was $0.32 million, a significant increase from $0 for the year ended December 31, 2024[462]. - The company reported a loss from operations of $12.6 million for the year ended December 31, 2025, compared to a loss of $27.2 million for the previous year, reflecting a decrease of $14.6 million[461]. - Net cash used in operating activities was approximately $14.8 million for the year ended December 31, 2025, primarily due to the net loss of $11.2 million[472]. - Cash provided by financing activities for the year ended December 31, 2025, was $10.6 million, significantly lower than $36.8 million in the previous year[475]. Clinical Development - Stenoparib is currently in a phase 2 clinical trial for advanced, recurrent ovarian cancer, showing promising results including a complete response in one patient and stable disease in two patients for over 14 months[408]. - The company expects to incur significant expenses and increasing operating losses over the next several years as it advances stenoparib through clinical trials and pursues regulatory approval[456]. Funding and Financing Activities - The company expects its current cash to fund operations for at least the next 12 months, but additional funding will be needed for future clinical and commercialization activities[416]. - In 2024, the company received $37.3 million from ATM sales and $1.3 million from promissory notes, while repaying $1.3 million of promissory notes and redeeming $3.5 million of preferred stock[419]. - The company entered into an At-The-Market Issuance Sales Agreement allowing for the sale of up to $50 million in common stock, with a commission of 3.0% on gross proceeds[427][428]. - In January 2026, the company entered a stock purchase agreement providing up to $6 million in additional equity financing[476]. Shareholder Actions and Stock Changes - The company decreased the number of authorized shares from 750,500,000 to 250,500,000, which was approved by stockholders[409][410]. - The company modified the conversion price of Series A Preferred Stock multiple times in 2024, impacting the number of outstanding Exchange Warrants significantly[422][424][425]. - The company amended the conversion prices of Series A Convertible Preferred Stock and 2024 Notes to $34.50 as of May 1, 2024, with 1,417 shares converted into 14,376,690 shares of common stock valued at $1.8 million[426]. - The company issued 35,000 shares of Series A Convertible Redeemable Preferred Stock for net proceeds of approximately $2.9 million on August 19, 2024[431]. - The conversion price of Series A Preferred Stock was revised to $0.4476, allowing for the conversion of 1,417 shares into 3,419,035 common shares[436]. - The conversion price was further amended to $0.405, increasing the number of Exchange Warrants outstanding to 10,882,028[437]. - The company incurred a deemed dividend of $0.6 million due to the redemption of the August 2024 Preferred Stock during the twelve months ended December 31, 2024[435]. - The company sold 9,719,173 shares of common stock for net proceeds of $9.7 million for the year ended December 31, 2025[429]. Legal and Regulatory Matters - A settlement with the SEC was reached in March 2025, resulting in a one-time civil penalty of $2.5 million[412]. - The company is subject to risks common in the biotechnology industry, including the need for marketing approval and successful commercialization of product candidates[439]. Research and Development - The company has entered into various research and development contracts, with payments recorded as expenses as incurred[444]. - Research and development expenses increased by $0.5 million to $6.6 million for the year ended December 31, 2025, primarily due to a $1.1 million increase in staffing costs[464]. - General and administrative expenses decreased by $5.1 million to $6.3 million for the year ended December 31, 2025, mainly due to a reduction in legal and professional fees[466]. - The company has no impairment charge for intangible assets as of December 31, 2025, following a full impairment charge of $9.7 million in 2024[465].

Funding and Grants - eXoZymes has received a total of $17,697,378 in grants since inception, with $4,058,367 awarded in 2025 and $1,048,302 in 2024[35] - The company has received a $50,000 grant from the Gates Foundation for terpene synthesis, highlighting its engagement with non-government funding sources[34] - The company received a grant of approximately $1,000,000 from the Department of Defense in October 2024 to support biomanufacturing efforts[198] Business Model and Strategy - The company is focusing on low-volume, high-value compounds for nutraceuticals, which can also serve as active pharmaceutical ingredients (APIs)[36] - eXoZymes aims to leverage AI-designed exozymes to create scalable and sustainable biosolutions, differentiating from traditional synthetic biology approaches[26] - The commercialization strategy includes a focus on nutraceuticals to accelerate time to market and generate early revenue streams[46] - eXoZymes plans to evaluate transitioning select compounds into formal pharmaceutical development programs after the initial focus period[41] - The company is focused on developing joint ventures and licensing agreements to optimize or replace existing products in mature markets, generating both short-term and long-term revenue[61] - The business model emphasizes partnerships to share costs, risks, and revenues, particularly in the nutraceuticals-with-pharmaceutical-potential sector[54] - eXoZymes plans to commercialize NCT through a capital-light model leveraging contract manufacturers, aiming for consistent quality and improved manufacturing efficiency[72] Technology and Innovation - eXoZymes' biomanufacturing platform offers a cell-free approach that enhances control, efficiency, and cost-effectiveness in producing small molecule natural products[49] - The technology enables higher titers, yields, productivities, and purity compared to traditional synthetic biology methods, addressing scalability challenges[50] - The proprietary platform achieves over 99% food/pharma-grade purity and 6× faster production cycles than conventional methods, with over 99% reaction yield at pilot scale[69] - eXoZymes is developing multi-step cell-free biocatalysis systems, distinguishing itself from competitors that primarily use simpler one to two-step pathways[93] - The company is focused on biomanufacturing processes tailored to nutraceutical and pharmaceutical production, particularly for rare cannabinoids[77] Market and Competition - eXoZymes believes that partnerships will be essential for realizing the full potential of exozyme biosolutions in various markets[42] - The company faces competition from various firms in the synthetic biology space, including those focusing on enzyme engineering and biofuels[95] - The company competes with established firms and emerging startups in the synthetic biology market, facing challenges from companies with greater resources and experience[129] Financial Performance - For the year ended December 31, 2025, total operating costs increased by 63.8% to $9,716,471 compared to $5,932,105 in 2024[188] - Research and development costs rose by 98.4% to $3,706,991 in 2025, primarily due to higher salaries, bonuses, and laboratory expenses[189] - Cash and cash equivalents decreased by 68.7% to $3,039,343 as of December 31, 2025, down from $9,719,310 in 2024[190] - The company reported a net loss of $9,158,734 for 2025, a 56.3% increase from the net loss of $5,861,335 in 2024[188] - Working capital decreased by $7,114,450 to $2,372,687 as of December 31, 2025, compared to $9,487,137 in 2024[195] - Total assets decreased by 54.2% to $5,971,517 in 2025 from $13,034,404 in 2024[190] - The company incurred cash used in operating activities of $6,502,040 in 2025, an improvement from $8,505,650 in 2024[201] Intellectual Property and Licensing - eXoZymes has a robust intellectual property portfolio, including patents related to enzyme engineering and biomanufacturing processes, providing a competitive advantage[73] - The initial license fee for the agreement with The Regents of the University of California was $6,000, with a continuing maintenance fee of $2,500 per year[75] - The minimum annual royalty starts at $15,000 and increases to $50,000 in the third year, with a 2% royalty on net sales of therapeutics products and 1% on all other products[75] - The aggregate payments made to the Regents from 2019 to December 31, 2025, total $400,211, including patent fees and maintenance fees[78] - The company holds exclusive licenses from The Regents of the University of California for cell-free synthetic biochemistry technology, which imposes various developmental milestone obligations[138] Risks and Challenges - The company believes there is substantial doubt about its ability to continue as a going concern due to anticipated funding shortfalls[200] - The company faces potential challenges in obtaining regulatory approvals for its novel bio-synthesized compounds, which may delay development and commercialization[113] - The company lacks manufacturing and distribution capabilities and plans to seek partners for commercialization, which is critical for generating product revenue[124] - Future collaborations are essential for research and commercialization, but risks include potential non-performance by collaborators and competition from their independent developments[126] - The company is currently concentrated on a small number of biosolution projects, which poses risks if these products cannot be commercialized[122] Corporate Governance and Compliance - The company incurs significant legal and compliance costs as a public company, which may impact its financial performance[147] - The company may not be able to maintain effective internal controls over financial reporting, which could lead to a loss of confidence in its financial statements[153] - The company has not reported any cybersecurity breaches during the fiscal year ended December 31, 2025, but acknowledges potential risks associated with cyber attacks[171] - The company has retained outside consultants to enhance its information technology and cybersecurity measures, focusing on continuous improvement[174] Employee and Workforce - As of December 31, 2025, eXoZymes has approximately 32 full-time employees, including 9 with doctoral degrees, and plans to expand its workforce across multiple departments[101] Market Conditions - The synthetic biology market is rapidly evolving, and eXoZymes must continuously adapt to market demands to remain competitive[112] - Potential recessionary indicators may impact the general business environment and capital markets, affecting the company's operations[213] - The company does not believe inflation has materially affected its operations, although it continues to monitor supply chain issues and tariffs[212]

Financial Performance - Revenue for Q4 2025 was $5.0 million, a decrease of 33.1% year over year, mainly due to lower CVD system revenue[3] - For the fiscal year 2025, revenue was $25.8 million, down 4.1% year over year, primarily due to lower SDC revenue[10] - The net loss for Q4 2025 was $1.3 million, or $0.18 per share, compared to a net income of $0.1 million, or $0.02 per share, in the prior year quarter[3] - The net loss for fiscal year 2025 was $1.6 million, or $0.23 per share, compared to a net loss of $1.9 million, or $0.28 per share, in fiscal year 2024[10] Orders and Backlog - Orders for Q4 2025 totaled $3.5 million, primarily driven by demand in the SDC business division for gas delivery equipment[3] - The backlog as of December 31, 2025, was $6.6 million, down from $8.0 million at September 30, 2025[3] Gross Margin - Gross margin for Q4 2025 was 22.1%, compared to 26.4% in the prior year quarter[3] Cash Position - Cash and cash equivalents as of December 31, 2025, were $8.7 million, down from $12.6 million as of December 31, 2024[10] Strategic Actions - The company entered into a definitive agreement to sell its SDC division for approximately $16.9 million in cash, expected to close in Q2 2026[6][7] - The company implemented a workforce reduction expected to reduce annual operating costs by approximately $1.8 million in fiscal 2026[3]